Merix unveils new over-the-counter genital herpes treatment
BARRINGTON, Ill. Merix Pharmaceutical unveiled its new Fast-Results! genital herpes treatment this month while attending the ECRM Cough, Cold and Allergy conference in Dallas.
The only OTC treatment for genital herpes, Fast-Results! answers an unmet need of people who suffer painful symptoms associated with genital herpes outbreaks. Designed to be used in conjunction with prescription medication, Fast-Results! also brings needed treatment to consumers who cannot afford prescription medication.
Fast-Results! genital herpes treatment is comprised of Merix’ patented technology Viracea, which contains an approved ingredient under the FDA OTC antiseptic/antimicrobial monograph, the company stated. At clinical trial, Viracea was shown to be effective in lesions caused by herpes.
According to Centers for Disease Control and Prevention, 16% of Americans currently suffer from genital herpes, which equates to approximately 37 million adults.
“We believe there is a very strong market need for this product,” stated Merix CEO Meryl Squires. Several major retailers have already committed to carrying Fast-Results! genital herpes treatment, Squires said. CVS will begin stocking in mid-May, soon thereafter followed by Rite Aid.
Sanofi-Aventis completes acquisition of Chattem
PARIS A leading global pharmaceutical company has completed its acquisition of a consumer healthcare products manufacturer.
Sanofi-Aventis said that Chattem Inc. officially has become a a wholly-owned subsidiary of the Sanofi-Aventis Group, strengthening its presence in the U.S. consumer healthcare market.
Sanofi-Aventis completed its tender offer of Chattem last month. There also has been speculation that the company is looking to make a stake in the OTC market with other acquisitions. Sanofi-Aventis said Thursday that the acquisition provides new channels for maximizing the potential of converting Sanofi-Aventis’ prescription medicines to over-the-counter products.
Chattem, Sanofi-Aventis’ U.S. consumer healthcare division, will be headquartered in Chattanooga, Tenn. and led by current Chattem CEO Zan Guerry. Guerry will lead the U.S. consumer healthcare business reporting to Greg Irace, president and CEO, Sanofi-Aventis U.S.
“The addition of Chattem to our worldwide portfolio of leading consumer healthcare businesses represents an important milestone in Sanofi-Aventis’ strategy to become a global diversified healthcare leader,” said Christopher Viehbacher, Sanofi-Aventis CEO. “Chattem’s existing sales, marketing and distribution teams and infrastructure provide a tremendous platform for future conversions of prescription medicines to OTC products in the U.S., and I am confident that Chattem will maximize the success of those conversions. I look forward to working with Zan Guerry and the Chattem leadership team, who will play a key role in the performance of our consumer healthcare activities.”
Hatch, McCain reach agreement over Dietary Supplement Safety Act of 2010
WASHINGTON Sens. Orrin Hatch, R-Utah, and John McCain, R-Ariz., have come to an agreement around McCain’s Dietary Supplement Safety Act of 2010 (S. 3002) where McCain will not support revisiting or revising the Dietary Supplement Health and Education Act of 1994, according to a letter from Hatch to McCain last week.
“I want to thank you for agreeing to withdraw your support for the provisions of S. 3002 that I believe would do great harm to the dietary supplement industry,” Hatch wrote. “More than 100 million Americans regularly consumer dietary supplements as a means of improving and maintaining healthy lifestyles. Therefore, continued access to these products is extremely important to them.”
Hatch and McCain appear to be joining forces, instead, in calling for full enforcement of existing laws, such as DSHEA.
Late last month, the Council for Responsible Nutrition voiced industry concerns around S. 3002, suggesting that the bill, if passed, may have unintended consequences, including forcing some supplements with a long record of safety off the market.
However, even though it appears that revisiting industry regulation may be off the table, supplement manufacturers should still be communicating with their legislators advised John Gay, CEO and executive director for the Natural Product Association. “[S. 3002] was a wake-up call for the industry, and we had better not fall back asleep,” he said. “Other members of Congress could pick up where McCain … left off. We need to keep up the pressure on Congress, and let them know that S.3002 and bills like it are not acceptable.”